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ABSTRACT
The single largest risk factor for aetiology of neurodegenerative diseases like 
Alzheimer’s disease is increased age. Therefore understanding the changes that 
occur as a result of aging is central to any possible prevention or cure for such 
conditions. Microglia, the resident brain glial population most associated with both 
protection of neurons in health and their destruction is disease could be a significant 
player in age related changes. Microglia can adopt an aberrant phenotype 
sometimes referred to either as dystrophic or senescent. While aged microglia have 
been frequently identified in neurodegenerative diseases such as Alzheimer’s 
disease, there is no conclusive evidence that proves a causal role. This has been 
hampered by a lack of models of aged microglia. We have recently generated a 
model of senescent microglia based on the observation that all dystrophic microglia 
show iron overload. Iron-overloading cultured microglia causes them to take on a 
senescent phenotype and can causes changes in models of neurodegeneration 
similar to those observed in patients. This review considers how this model could be 
used to determine the role of senescent microglia in neurodegenerative diseases.
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Abbreviations:
AD: Alzheimer’s disease
CNS: central nervous system
CSF1: colony stimulating factor 1
CSFR1: CSF1 receptor
Eif2a: Eukaryotic translation initiation factor 2A
HDLS: hereditary diffuse leukoencephalopathy with spheroids
IFNγ: interferon gamma
IL: interleukin
Kv1.3: Potassium voltage-gated channel 3
LPS: Lipopolysaccharide
LRRK2: Leucine rich repeat kinase 2
mTOR: mammalian target of rapamycin
PD: Parkinson’s disease
ROS: Reactive oxygen species
SA-β-GAL: Senescence-associated beta-galactosidase
SASP: senescence associated secretory phenotype
SH-SY5Y: a human neuroblastoma cell line
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SIRT-1: sirtuin 1
TGFβ: Transforming growth factor beta
TLR: Toll-like receptor
TNFα: Tumor necrosis factor alpha
TREM2: Triggering receptor expressed on myeloid cells 2
sTREM2: soluble TREM2
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INTRODUCTION
Human aging results in gradual loss of normal functioning. Changes at the cellular 
level are believed to contribute to this process (Lopez-Otin et al. 2013). Aging within 
the human brain is of considerable interest because age related changes there are 
frequently irreversible and can lead to changes that severely impair normal activity
(Damoiseaux 2017). Furthermore, the changing cellular environment of the aging 
brain is the single largest contributing factor to the increased likelihood of developing 
a neurodegenerative disease such as Alzheimer’s disease (AD) (Pierce et al. 2017).
Our understanding of the cause of aging is limited. Our population currently 
experiences unprecedented long-life expectancy, which implies that the incidence of 
age-related diseases, like neurodegenerative disease, will increase dramatically. 
Therefore, there is a great need to more fully understand the aging process in order 
to circumvent those aspects which initiate neurodegenerative diseases. 
Understanding aging at a systemic level is equally challenging, implying the best 
current approach is to understand cellular aging (Barzilai et al. 2018). For the brain, 
this implies understanding how the molecular processes in neurons and glial cells 
change as we age and also how the interactions of these cells are affected by such 
changes.
Neuronal survival and normal function may be affected by cellular changes that are 
internal to them. However, neurons are highly dependent on glia for many reasons
(York et al. 2018). Therefore, the aging of glia can have significant impact on 
neuronal viability as well as the proteins they express or even protein turn-over
(Verkhratsky et al. 2014, Brown 2009). The potential role of glia in 
neurodegenerative disease has been discussed for some decades now (Henstridge
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et al. 2019, Itagaki et al. 1989). However, such studies have largely focussed on 
abnormal glia behaviour such as activation of microglia or the formation of astrocyte 
scars and the secretion of pro-inflammatory cytokines (Liddelow 2019). However, 
there is increasing evidence that glia cells undergo an aging process and this may 
also impact neurodegenerative disease progression (Holtzman & Ulrich 2019, Cohen 
& Torres 2019, Spittau 2017). These glial cells can be described as either senescent 
or dystrophic (Streit et al. 2014). Similar in some ways to the activated state, such 
glia secrete an altered array of molecules, especially cytokines and also lose 
supportive roles that normally shield neurons from various assaults (Lopes et al.
2008). 
It is currently unclear whether the two terms (senescent and dystrophic) describe 
one state or are actually two different states. Senescent can also imply different 
states. Originally derived from the study of cancer cells, cellular senescence implied 
a loss of the ability to divide (Campisi 2013). However, more recently this has come 
to imply an age related change in the secretory profile, as in the senescence 
associated secretory phenotype (SASP) (Coppe et al. 2008, Chinta et al. 2015). 
Dystrophic on the other hand is a term derived from a morphological change as 
observed from the study of brain sections (Streit et al. 2004). These changes in cell 
structure cannot be easily associated with a molecular change in cells as there is 
currently no easy way to identify such cells outside of these morphological 
differences (Streit et al. 2014). A recent publication has highlighted how critically 
important understanding glial aging may be. The promoter for a molecule associated 
with cell cycle arrest (p16Ink4a) was used to drive the expression of a suicide protein 
in glial cells in a transgenic mouse model (Bussian et al. 2018). In this tau based 
model of neurodegeneration, the destruction of senescent (non-dividing) glia cells 
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greatly reduced observed pathology. This implies that destruction of senescent glia 
may greatly benefit prognosis in cases of neurodegenerative diseases. However, 
what remains unclear is how this would be achieved in patients or exactly which 
population of glia should be targeted.
Impairment of neuronal activity seen in both aging and diseased states is mostly 
likely to be caused by microglia that have become senescent/dystrophic. However, a 
conclusive demonstration of a role for senescent microglia in neurodegenerative 
disease remains absent. Such evidence requires the ability to specifically identify 
and target these cells. To this end there have been recent attempts to create in vitro
models of senescent microglia and verify that they induce changes in neurons that 
reflect changes seen in neurodegenerative diseases (Angelova & Brown 2018b, 
Angelova & Brown 2018a). This review will present the evidence that such new 
models of senescent microglia are paving the way to their in vivo identification and a 
fuller elucidation of their role in brain aging and disease.
ROLE OF MICROGLIA
Neurons and macroglia such astrocytes and oligodendrocytes share a similar 
embryonic origin, deriving from the neural tube which arises from the ectoderm
(Stiles & Jernigan 2010). Microglia in comparison, have an origin outside of this and 
enter the brain following migration and take up residence there prior to the formation 
of the blood brain barrier. The exact origin of microglia has been subject of some 
controversy. While it is well established that microglia derive from macrophages that 
migrate into the developing nervous system, the initial starting place for that 
migration has different potential sources. Initial experiments in mice suggested that 
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microglia had a bone marrow origin (Hickey & Kimura 1988). It was later suggested
that the radiation used to generate mouse chimeras caused brain inflammation 
which was the reason for the migration of bone marrow precursors (Mildner et al.
2007). It is now accepted that microglia are derived from yolk-sac macrophage 
precursors and are genetically different from blood mononuclear cells (Prinz & Priller 
2014).
Functionally, microglia are largely considered to be the immune cell of the brain, 
remain in non active or surveillance state (ramified) unless induced to activate to 
deal potential threat to the neurons (Figure 1). Microglia play an important role in 
development of the CNS and also CNS homeostasis in health and disease. They are 
not the only immune cell in the brain. Other immune cell types include but are not 
limited to macrophages and lymphocytes (Strazielle et al. 2016).Perivascular, 
meningeal and choroid plexus macrophages also reside at the CNS interface 
(Goldmann et al. 2016). Additionally, peripheral macrophages are capable of 
migrating through the blood-brain barrier.  However, unlike other macrophages,
microglia haven’t been found to be continuously renewed from myeloid progenitor 
blood cells and instead they increase in number through cell division (Askew et al.
2017). As the microglial population is predefined early in development it is not 
surprising that they are vulnerable to physiological disturbances such as ageing that 
can contribute to the development of psychiatric and neurodegenerative diseases. 
Until recently, microglia were viewed under the misconception that they were static 
bystanders and only acted in conditions of injury or disease. Now it has been shown 
that microglia constantly interact with different CNS components and have a central 
role in the maintenance of brain homeostasis. In development microglia migrate from 
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the yolk sac to the CNS at approximately the same time neurons are formed. Thus, 
microglia participate in many important events in the developing CNS such as 
neurogenesis, apoptosis, synaptic pruning and modelling of neural networks (Pont-
Lezica et al. 2014, Hoshiko et al. 2012, Paolicelli et al. 2011, Prinz & Priller 2014).
In the adult organism microglia maintain that multifunctionality and are capable of 
quickly adapting to changing conditions to adopt a variety of states. In the healthy 
brain microglia maintain a quiescent “surveillance” phenotype which is maintained by 
soluble factors secreted by healthy neurons and increased levels of microRNA-124
(Conrad & Dittel 2011).  Microglia in the surveillance state (previously known as the 
resting state) can be recognized by their ramified morphology. Ramified microglia 
constantly screen the brain with their highly motile processes for signs of damage-
associated molecular pattern molecules (DAMPs) such as ATP or calcium release 
(Nimmerjahn et al. 2005). The most morphologically adaptable and motile cell in the 
brain, they have been reported to constantly extend and protract their processes and 
be able to contact the synapses of neurons and secrete communication molecules to 
regulate them (Panatier & Robitaille 2012, Hristovska & Pascual 2015).
If signs of damage are detected the microglia migrate to the site of injury and convert 
to an activated or reactive state (Nimmerjahn et al. 2005). The morphology of 
microglia is an identifying characteristic of their activation state. Non-phagocytic 
reactive microglia display a thickening of their branches, upregulation of MHCI/II, 
secretion of proinflammatory cytokines and reactive oxygen species (ROS) (Colton 
2009, Rock et al. 2004, Gehrmann et al. 1995). As they progress in their activation 
they can assume a phagocytic state which is characterised by a large ameboid 
shape and in addition to the aforementioned inflammatory signals they gain the 
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ability to phagocytose material and display it for T-cells (Gehrmann et al. 1995, Rock 
et al. 2004, Aloisi 2001). There is also evidence that microglia can support re-
myelination following axonal damage. Depletion of microglia in experimental models
of re-myelination showed significant impairment implying a supportive role for 
microglia (Lloyd & Miron 2019).
It is thought that depending on the signals they receive microglia can polarise to 
states similar to M1 and M2 in macrophages where M1 is pro-inflammatory and M2 
is phagocytic and aids in tissue regeneration (Ransohoff 2016). However, the M1/M2 
model fails to account for the complexity of the brain environment and the variety of
signals microglia are exposed to by different cell types. Sequencing of microglial 
transcriptomes in surveillance and reactive states has found their reactive signature 
is diverse and difficult to characterise (Hirbec et al. 2018, Wes et al. 2016). Some 
have argued that the M1/M2 distinction should be done away with altogether as it 
was developed through in vitro experiments in a simplified environment that cannot 
be replicated in vivo (Ransohoff 2016). In the human brain microglia are found to 
adopt intermediate activated phenotypes demonstrating the complex role these 
myeloid cells are expected to play in the brain. That has led to the agreement that 
describing activation states in macrophages including microglia is best done by 
referring to the stimulating molecule that produced the reactive state (Wes et al. 
2016). Just as it has been proven difficult to distinguish specific activation states in 
microglia on the molecular level, so it has been hard to identify the specific 
morphology of those cells in live tissue. Historically, most observations of microglia 
have focused on diseased states and on fixed tissue. As mentioned above microglia 
are highly reactive cells that can change both their morphology and their molecular 
signature with changing conditions. With the emergence of more accurate 
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techniques to image live tissue such as two-photon laser scanning microscopy we 
are beginning to get a better understanding of microglial motility and morphological 
spectrum in physiological conditions (Hristovska & Pascual 2015, Stopper et al.
2018). 
Microglial priming is a process driven by changes in the molecular environment 
including exposure to molecules that drive proliferation (Perry & Holmes 2014). It 
consists of the increased reactivity of microglial cells upon stimulation. It has been 
reported in aged mice upon stimulation with IL-1β and IL-12 (Lee et al. 2013). Two 
types of priming have been reported, classic which has been linked to exposure to 
IFN-γ and is neurotoxic, and alternative – linked to exposure to IL-4 and IL-13 and 
suggested to be neuroprotective (Hickman et al. 2013). Toll-like receptors 2,3 and 4 
have been shown to be essential for the classical priming process (Facci et al.
2014). The transcriptional signature of microglial priming seems to be dependent on 
the High mobility group box 1 (HMGB1) and inhibiting it prevents microglia from
entering a primed state (Holtman et al. 2015, Fonken et al. 2016).
DYSTROPHIC AND SENESCENT MICROGLIA
Evidence of microglial aging was first identified in the brains of aged individuals by
morphology and immunohistochemistry (Streit et al. 2004). They were found to be 
widespread and were characterised by a dystrophic morphology that included 
process deramification, shortening, gnarling and beading, the formation of spheroids 
and cytoplasmic fragmentation (Figure 2). It was this type of dystrophic microglia that 
were also found to store iron through elevated levels of ferritin (Lopes et al. 2008). 
The accumulation of iron in microglia with age is an interesting phenomenon as 
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microglia are not the main iron-storing cell type in the brain and iron may play a 
major role in age-related microglial dystrophy. 
Aging microglia have also been found to have an altered surveillance phenotype with 
less dendritic branching and reduced process motility. When confronted with injury 
they exhibit lower migration rates and have a more sustained inflammatory response 
in reaction to damage (Damani et al. 2011). This characteristic increase in low-grade 
inflammation is typical of the aging brain with higher levels of pro-inflammatory 
cytokines and lower levels of anti-inflammatory cytokines detected in aged brains
(Sparkman & Johnson 2008). Microglia have been found to be very long-lived cells in 
a study that monitored them over the mouse lifespan (Weinberg 2008). This puts 
microglia forward as ideal candidates for chronic senescence and explains how 
microglial senescence can potentially have a major effect in neurodegenerative 
diseases. As microglia are the main immune cells in the brain the way they affect 
inflammation in the brain has been studied extensively. Aged microglia have been 
found to not only change their cytokine signature to a pro-inflammatory one but also 
exhibit reduced phagocytosis and increased ROS production(Koellhoffer et al. 2017). 
These changes result in microglia not only failing to maintain neuronal health but 
also impairing it thus contributing to the possible development of neurodegenerative 
diseases. The senescence associated secretory phenotype (SASP) is a newer 
method of characterising aged microglia (Streit et al. 2014).  SASP is an integral part 
of the characteristics of a senescent cell. It includes many signalling molecules such 
as proinflammatory cytokines, chemokines, ROS, growth factors and proteases that 
can cause a significant negative impact on surrounding cells and is linked to aging 
and neurodegenerative disease (Chinta et al. 2015). 
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The criteria for SASP differ from cell type to cell type, but microglia have been found 
to undergo SASP-congruent increases in TNFα, IL1β, IL-6 and IL-8 (Sierra et al.
2007). Interestingly, one of the criteria for developing SASP in a cell type is DNA 
damage (Coppe et al. 2010). DNA damage has been found to increase in aged 
microglia, particularly in mitochondria (von Bernhardi et al. 2015, Hayashi et al.
2008). Telomere shortening is also found in human and rat aged microglia, 
especially in association with dystrophy (Flanary & Streit 2004). It is likely that a 
SASP signature will be established for aging microglia in the near future. 
The genomic signature of aged microglia has been of great interest since the advent 
of next generation sequencing technologies. Unfortunately attempts to characterise 
them have yielded varied and often conflicting results with no clear and consistent 
specific genetic or protein markers for aged microglia emerging (Crotti & Ransohoff 
2016, Spittau 2017, Wes et al. 2016, Olah et al. 2018). The aged microglia in the 
mouse retina exhibited significant changes in genes controlling inflammation 
including the NF-κB signalling pathway and upregulated complement genes C3 and 
complement factor B (Ma et al. 2013). A study on the microglial sensome of aged 
mice reported a shift in microglia to a more neuroprotective phenotype with age with 
a particular decrease in genes related to sensing endogenous ligands but not 
phagocytosis or exogenous sensing (Hickman et al. 2013). Those two studies 
suggested that microglial aging is associated with neuroprotection. In contrast, 
another study on aged mouse microglia gene expression reported decreased 
expression in cytoskeletal reorganization proteins suggesting aged microglia are less 
motile. They also observed increased expression of cytokine genes suggesting that 
microglia have a reduced ability to migrate to sites of injury and stimulate 
inflammation, suggesting they play a less neuroprotective role (Orre et al. 2014). A 
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recent gene expression meta-analysis reported that aged microglia display a 
different expression signature from LPS or IL-4 stimulated microglia, suggesting they 
don’t exhibit a classic activation state but do overlap with primed microglia which are 
also neurotoxic (Holtman et al. 2015). The few datasets currently published on 
human microglia aging transcriptome point in the direction that mouse and human 
microglia may age differently (Galatro et al. 2017, Olah et al. 2018). Olah et. al. 
(2018) detected significant changes in more than 2000 genes in aged microglia. The 
pathways that were upregulated were involved in amyloid fibril formation while the 
TGF-β signalling pathway was downregulated thus suggesting a more pro-
inflammatory phenotype for aged microglia. Other upregulated genes were linked to 
SASP, cytokine signalling, DNA methylation and maintenance among others. That 
study also validated their expression data with proteomic data as well, finding that 
many proteins from the amyloid fibril formation gene set were still upregulated in 
aged microglia. The changes detected in the Galatro et al. (2017) study involved 
reduced expression of genes related to the actin cytoskeleton and cell surface 
sensor receptors and alterations in immune response genes. Comparison of this 
dataset with an existing mouse dataset found very limited overlap in gene expression 
changes between the two organisms. It is possible that this is due to isolation 
methods of the cells that may alter their gene expression, but it could also be due to 
microglia exhibiting different aging signatures in different parts of the brain (Grabert
et al. 2016). The differences detected between human and mouse datasets could 
potentially be explained by the vast disparity in the lifespans of the organisms and of 
the microglia themselves as a consequence but also by the environments that 
humans are exposed to that laboratory mice never would. It seems that gene 
expression studies can reproducibly detect changes in larger networks in aged 
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microglia such as inflammatory response, cytoskeletal remodelling, and ligand 
sensing; but it’s difficult to identify specific biomarkers for identifying aged microglia 
just from expression data (Holtman et al. 2015). 
The description of “aged” microglia may include a number of different distinct 
phenotypes and currently the term is loose and uncertain (Koellhoffer et al. 2017). As 
mentioned above, the term dystrophic describes all the visually altered microglia in 
the aged brain, identifiable by their elevated iron content (Simmons et al. 2007). 
However, “senescent” microglia may include these cells and others. Indeed, the term 
senescent may not be sufficient to cover all “aged” microglia and there may be a fine 
line between such microglia and primed microglia which may simply be more 
abundant with age (Niraula et al. 2017). Furthermore, it has recently been suggested 
that if senescence is strictly defined as cell that can no longer divide, then a second 
“aged” phenotype call be described which has been termed epigenetic aging 
(Kabacik et al. 2018). This suggestion comes from observations on methylation 
patterns that change with age and may contribute to altered gene expression 
patterns that result from the aging process. However, whether this is important for 
microglia remains to be determined and presently the SASP remains the only widely 
accepted phenotype for aged microglia.
Cellular senescence has been shown to occur in many replication competent cell 
types in the brain, as well as microglia, and is thought to be a major contributor to 
inflammation in the brain in old age (Chinta et al. 2015). As mentioned above 
senescence is classically characterised by arrested growth due to elevated DNA 
damage and oxidative stress that results in increased SA-β-GAL activity, p16INK4a
expression and the SASP among others. In microglia, iron accumulation seems to be 
the single clearest way to identify senescent microglia, while whether they can still 
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proliferate or not cannot be assessed. Interestingly, cells in vitro have been found to 
also naturally accumulate iron as a characteristic of the process of acquiring 
senescence (Masaldan et al. 2018, Killilea et al. 2003). 
A truer understanding of aged/senescent/dystrophic microglia will only come about 
with a valid way identifying them. Once a valid molecular tag can be found this will 
lead to their isolation and characterisation. In chronic senescence which would be 
the type present in brain microglia, SASP can be more heterogenous than in cases 
of in vitro replicative senescence (van Deursen 2014).  Nevertheless, understanding 
better how microglia undergo senescence by characterising their specific senescent 
phenotype and SASP is very important for determining how they affect the molecular 
environment of the aging brain, especially in terms of inflammation.
ROLES OF MICROGLIA IN NEURODEGENERATION
A role for microglia in neurodegenerative disease has been postulated for some time
(Hickman et al. 2018, McGeer et al. 1993). This is because activated microglia have 
been found in association with disease markers such as plaques of β-amyloid in AD
(Mattiace et al. 1990). However, there has been recent discussion as to whether 
these microglia are activated or dystrophic and which form is mostly likely to be 
causative in the relevant pathological changes (Navarro et al. 2018). Even 
considering a possible activated state, evidence suggest that both markers of M1 
and M2 activation states are present in AD (Hopperton et al. 2018). Other studies 
suggest both activation states are present at different times (Tang & Le 2016). 
Single-cell RNA-sequencing studies also suggest that there is continuous, 
heterogeneous spectrum of states present in the brains of mouse models of AD (von 
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Maydell & Jorfi 2019). A comparison of microglial markers between individuals with 
AD and high-pathology but cognitively normal controls showed that microglial 
activation is increased in AD, suggesting that microglial activation is not simply a 
reaction to AD pathology such as β-amyloid deposition (Hopperton et al. 2018). It is 
possible microglia are pushed towards a more proinflammatory phenotype through 
age-related changes. 
Mutations in genes related to microglial function have been linked to 
neurodegenerative disease risk. For example, a rare variant of the TREM2 gene 
leads to an increase in the risk for developing AD 3-4 times and more severe 
pathology. Recent evidence also suggests that TREM-2 knockout increases Aβ-
related pathology (Griciuc et al. 2019). In the context of both aging and 
neurodegeneration TREM2 is thought to interact with APOE to activate pathways 
linked to microglial activation, survival and phagocytosis (Krasemann et al. 2017). 
Loss of function mutations in TREM2 also cause a rare deadly disease (Nasu-
Hakola Disease) that presents with neurodegenerative symptoms and bone cysts 
(Yeh et al. 2017).  The expression of soluble TREM2 by aged microglia of a mouse 
AD model was also found to rise with both amyloid load and markers of microglial 
activation over time, suggesting that sTREM2 also plays a role in the 
neurodegenerative process (Brendel et al. 2017). The expression of TREM-2 also 
impacts other neurodegenerative diseases. As an example, knockout of TREM-2 
causes α-synuclein–induced neuronal loss in a model of PD (Guo et al. 2019).
Leucine rich repeat kinase 2 (LRRK2) is a protein expressed highly in microglia that 
is implicated in both microglial activation and lysosomal degradation. Mutations in 
LRRK2 are the most common in both familial and sporadic Parkinson’s disease 
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(PD). They are thought to result in increased proinflammatory signalling and possibly 
prevent microglial cells from degrading protein aggregates (Schapansky et al. 2015, 
Gillardon et al. 2012). CSF1R is a cell surface receptor for the cytokine CSF1 which
in the brain is expressed predominantly in microglia and is a mediator for microglial 
proliferation and differentiation. CSF1R loss of function mutations have been shown 
to cause hereditary diffuse leukoencephalopathy with spheroids (HDLS), a 
neurodegenerative disease that has symptoms of dementia and parkinsonism 
among others (Rademakers et al. 2011). CD33 is another microglial cell surface 
receptor that has both been found to be upregulated in AD and has a rare variant 
that confers increased risk of developing AD. CD33 acts to reduce microglial 
proliferation and phagocytosis and thus exacerbates AD pathology (Griciuc et al.
2013, Malik et al. 2013). These examples show that microglial function is essential to 
maintaining neuronal homeostasis and health and thus any disruption in microglial 
function can result in neurodegeneration.
As immune cells, microglia have been found to react to the presence of misfolded 
proteins in both AD and PD. Microglia are well known to be activated by the 
presence of β-amyloid and to cluster around sites of amyloid plaques (Hansen et al.
2018). Exposure to β-amyloid causes a change within the metabolism of microglia
changing their energy dependence to glycolysis (Baik et al. 2019). This impairs 
microglia functioning in the activated state. This could be reversed with interferon-γ,
which was found to be beneficial in AD model mice. This suggests metabolic 
correction of microglia could be effective in the treatment of AD (Baik et al. 2019). 
As the main protein that aggregates in PD, α-synuclein can also interact with 
microglia. Microglia have been shown to react to aggregated α-synuclein but not to 
monomeric through TLR receptor activation (Beraud et al. 2013, Fellner et al. 2013). 
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The TLR2 receptor has been shown to be activated by the most likely toxic form of α-
synuclein aggregates – β-rich oligomers (Kim et al. 2013). Additionally, microglia can 
also become activated through the detection of neurons under stress. Activated 
microglia secrete IL1β and TNFα which induce the synthesis of chemokines that
have been found to contribute to neuronal demise through the recruitment of 
neutrophils and monocytes from blood (Rock et al. 2004). Through the secretion of 
proinflammatory signals and ROS activated microglia can lead to the retrograde 
apoptosis of neurons that are connected to the degenerating neurons thus spreading 
the pathology. Therefore, through inappropriate action microglia are capable of 
perpetuating neurodegeneration in a feedback loop of inflammatory signalling (Perry
et al. 2010). 
As phagocytes, one of the roles of microglia is to clear any cellular debris and protein 
aggregates that they encounter. Therefore, one of the functions of microglia is 
degradation of β-amyloid (Ries & Sastre 2016). However, aging microglia lose their 
ability to clear β-amyloid effectively from the extracellular space.  In mouse models 
aged microglia have been found to have reduced expression of β-amyloid degrading 
enzymes and reduced phagocytosis (Hickman et al. 2008). It is thought that in AD 
microglial function is impaired by the mere presence of β-amyloid aggregates, thus 
leading to a self-perpetuating cycle of increased β-amyloid accumulation and further 
damage. A systematic review of microglial markers in AD found that most studies 
observed increases in markers related to microglial activation, but no significant 
difference in overall microglial markers. They also found no difference in overall cell 
counts suggesting that microglial number does not increase in AD, but microglial 
levels of activation do (Hopperton et al. 2018).
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Inflammation and ineffective protein clearance are strongly linked in 
neurodegeneration. It has been shown that microglia play a major role in the 
pathology of AD and Parkinson’s disease by driving inflammation in the brain 
(Subramaniam & Federoff 2017). In fact, in a mouse model, eliminating microglia 
didn’t affect amyloid deposition but prevented neuronal loss and degeneration and 
also resulted in improved cognition (Spangenberg et al. 2016, Dagher et al. 2015). 
Reducing inflammation by the use of NSAIDs is also linked to a lower risk of 
developing PD (Gagne & Power 2010). In an organotypic cell culture model of β-
amyloid accumulation in the aged brain, old microglia’s ability to clear β-amyloid was 
rescued by the presence or the conditioned medium of young microglia, suggesting 
that the effects of microglial aging on amyloid deposition can be reversed (Daria et 
al. 2017).
SENESCENT MICROLIA AS THE LINK BETWEEN AGING AND 
NEURODGENERATION 
Senescent microglia present both the impaired neuroprotective ability and the low 
but sustained secretion of molecules that drive inflammation seen in 
neurodegeneration (Koellhoffer et al. 2017). Dystrophic microglia have been 
identified in both aged brains and the brains of patients with neurodegenerative 
disease. They have been found near sites of tau pathology and amyloid plaques of 
AD brains and near Lewy bodies in dementia with Lewy bodies brains (Lopes et al. 
2008, Streit & Xue 2014, Streit & Xue 2016, Streit et al. 2009, Streit 2004).
Aged microglia in models of β-amyloid load that exhibited a lower phagocytic ability 
were also found to express the cytokines TNFα and IL-1β, unlike microglia that did 
phagocytose β-amyloid (Hickman et al. 2008). The expression of inflammatory 
cytokines is thought to also drive further microglial damage and perpetuate the AD 
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pathology. Microglia have also been shown to be able to internalise and degrade 
extracellular α-synuclein aggregates in a cell culture study, an activity that is 
apparently controlled by the activation state of the cells as it was reduced by 
activation with lipopolysaccharide (LPS) (Lee et al. 2008). 
The role of iron-rich microglia in neurodegenerative disease cannot be ignored. 
Ferritin-positive dystrophic microglia have also been found associated with amyloid 
plaques and neurofibrillary tangles (Streit et al. 2014). Iron also accumulates in AD 
brains in the hippocampus and in particular in the amyloid plaques of AD patients
(Raven et al. 2013, Smith et al. 1997). It is possible that iron together with other 
metal ions plays a role in the toxicity of β-amyloid oligomers (Tabner et al. 2010). 
Iron appears to also accumulate excessively in regions affected by Parkinson’s 
disease such as the substantia nigra and is associated with Lewy bodies where 
dystrophic ferritin positive microglia have been identified (Xu et al. 2017). Disruption 
in iron homeostasis has also been linked with a higher secretion of proinflammatory 
cytokines in microglia in vitro (Wang et al. 2013). Furthermore, short-term iron 
exposure has been found to induce rat primary microglia to potentiate neurotoxicity 
(Zhang et al. 2014). Exposure to iron has been linked to an increased risk of 
developing PD (Hare et al. 2017, Caudle et al. 2012, Peng et al. 2007). 
Neuromelanin, a protein that stores iron in neurons can be phagocytosed by 
microglia attracted to degenerating neurons, thus increasing the iron load of those 
cells. Interestingly, it has been demonstrated that neuromelanin phagocytosis can 
induce increased release of proinflammatory cytokines and ROS, thus driving 
inflammatory processes that can contribute to neuronal degeneration further
(Rathnasamy et al. 2013). It is possible that iron accumulation in microglia could be a 
protective mechanism from iron toxicity in the brain which then can proceed to 
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damage the microglia themselves and induce the accelerated aging signature seen 
in neurodegeneration (Krabbe et al. 2013).
MODELS OF AGED MICROGLIA
The study of aging microglia is important not only in terms of understanding their 
phenotype and gene expression, but also in understanding what their role is in both 
the aging of the CNS and in neurodegenerative diseases. Thus, having models of 
aging microglia that can be used to study their effect on neurons is extremely 
important. Obviously, aging microglia can be found in aged animals and some 
studies have utilised them in the study of senescence (Sierra et al. 2007, Griffin et al.
2006, Letiembre et al. 2007, Stichel & Luebbert 2007, Perry et al. 1993, Godbout et 
al. 2005). Unfortunately, using aged animals for experiments can be exceedingly 
expensive and time consuming, thus making them very impractical. Additionally, 
despite some reported methods, isolating and maintaining aged microglia in culture 
has, by and large, proven to be very difficult (von Bernhardi et al. 2011).  Some have 
made the case for the importance of studying age-related diseases in aged models 
being important enough to be worth the extra costs. However, currently it is just as 
difficult to obtain aged animals as ever (Johnson 2015). Transgenic models of 
accelerated aging are another potential avenue for observing microglial aging. The 
Ercc1(-/Δ) transgenic mouse model displays accelerated aging through DNA-repair 
deficiency (Schermer et al. 2013). This model has shown age-related changes in 
microglia (Raj et al. 2014). Another model of accelerated aging is the mTerc−/− 
mouse that exhibits telomere shortening whose microglia exhibit some signs of 
senescence and priming (Raj et al. 2015). An alternative to a full animal model can 
be cell culture models of aged microglia. One study has reported that microglia 
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isolated from neonatal mice start resembling aged microglia with time in culture, 
including reduced phagocytic ability, reduced motility, reduced autophagy, and 
changes in microRNAs and SA-β-galactosidase activity (Caldeira et al. 2014). 
However, these cells didn’t exhibit the SASP expected from aging microglia. 
Additionally, at 16 days this model is very short lived, thus again making it 
impractical for the study of neurodegeneration. Another method to induce age-like 
changes in microglia has recently been presented by Park et al. (Park et al. 2019). 
By treating primary rat microglial cultures with the drug dexamethasone (a 
corticosteroid) they simulated chronic stress inflicted by steroid hormones that 
microglia experience over time with aging. The microglia in this model exhibited 
increased SA-β-galactosidase activity, increased expression of tumour suppressor 
genes and dysfunctional phagocytosis similarly to senescent cells. However, they 
also showed increased autophagy, decreased expression of inflammatory genes and 
decreased cytokine release which is unlike aged microglia.
The observation that dystrophic microglia can be identified by high ferritin and thus 
iron content provided us with a potential avenue to generate a model of aged 
microglia (Brown 2009). The universality of this finding suggests that this is a 
significant observation. Given that iron has the potential to initiate macromolecule 
altering oxidation through Fenton and Haber-Weiss reactions, we theorized that, 
even though the aged phenotype in vivo occurs over time, it might be possible to 
induce similar changes through overloading microglia with iron in culture. We used 
both primary mouse microglia and human and mouse microglia cell lines and 
exposed them to high iron concentrations. These different microglia all showed 
significant retention of the iron along with changes in morphology, cytokines and 
ROS (Angelova & Brown 2018b, Angelova & Brown 2018a). This suggests the 
P a g e  24
adoption of an altered secretory profile similar to SASP. While one of the cell lines 
showed a decreased rate of proliferation, this was not universally observed. 
However, as mentioned, it remains unclear as to whether loss of proliferative ability 
is a valid indicator of senescent/dystrophic phenotype for a cell type that is meant to 
be able to able to divide as part of its normal activities. Changes in other markers of 
both aging and senescence were also observed such as altered expression of the 
proteins SIRT-1, Kv.1.3 and altered glutamate release (Angelova & Brown 2018b, 
Angelova & Brown 2018a). Lastly, we looked at cellular processes that are linked to 
altered cellular function, namely autophagy and ER stress. By monitoring proteins 
associated with both processes such mTOR and Eif2a, we were able to demonstrate 
that our model aged microglia showed increased ER stress and decreased 
autophagy (Angelova & Brown 2018a). Altogether, the changes we observed in our 
iron-overload based model of aging microglia were similar to both senescence and 
dystrophic alteration (Figure 3).
While changes in the behavior and function of microglia may be indicative of them 
adopting an age-related phenotype, greater evidence was obtained in experiments 
that they are able to induce changes in a neuronal cell line that are reminiscent of 
changes observed in neurodegenerative diseases. One of the most respected 
changes in AD, associated with its onset and pathology is the accumulation of β-
amyloid. We were able to induce increased survival of β-amyloid in cultures of SH-
SY5Y cells when treated with conditioned medium from our model aged microglia. 
We demonstrated that this was the result of the altered phenotype of the microglia in 
that they secreted less insulin-degrading enzyme (IDE), which is one of the main 
enzymes associated with β-amyloid turnover. We showed that this changed in the 
microglia was a result of decreased autophagy-related release of IDE. This verified 
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that causing an aged related change in model microglia could induce an AD related 
change, increased levels of β-amyloid (Angelova & Brown 2018a).
In PD, the symptoms of the disease are a result of the destruction of dopaminergic 
neurons. The potential mechanism for this loss is death induced by toxic species of 
α-synuclein. The ability of α-synuclein to aggregate and generate toxic species is 
highly dependent on its cellular concentration. Therefore, anything that increases α-
synuclein levels in cells is linked to increased risk of generating such toxic oligomers.
We demonstrated that conditioned medium from our model aged microglia could 
induce increased expression of α-synuclein in SH-SY5Y neuronal cells through a 
NF-κB regulated pathway related to increased levels of TNF-α secreted by the 
microglia (Angelova & Brown 2018b). Additionally, we found that this conditioned 
medium induced increased aggregation of α-synuclein, reduced ferrireductase 
activity and reduced tetramer formation. All of these changes are associated with 
Parkinson’s disease. The implication is that our model aged microglia are able to 
induce changes in neuronal cells related to the pathology of Parkinson’s disease and 
adds further verification of the utility of this model to study both aging and the impact 
of senescent microglia on neurodegenerative disease.
We feel that given this evidence we have developed a robust and easy to generate 
model of aged/senescent microglia that could be used to further study both the aging 
process and the role of microglia in neurodegenerative diseases. However, greater 
support for this would be the application of this aged microglia model in vivo. It is this
very important to determine if iron-overloaded microglia transplanted into mouse 
brains would induce phenotypic changes in neuronal cells similar to those seen in 
the culture models. For this to be achieved control and iron-overloaded microglia 
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could be transplanted into live rodent brains. This has been previously attempted 
with both primary and cell line microglia (Leovsky et al. 2015, Narantuya et al.
2010a, Narantuya et al. 2010b, Watanabe et al. 2002, Takata et al. 2007). The 
observation of either neurodegeneration or age-related changes in a transplantation 
model based on iron-overloaded microglia could possibly generate the ultimate aging 
model and reduce the time required to produce data on the nature of brain aging. 
However, even if this is achievable one final piece of the puzzle remains currently 
elusive. It is important to determine how increasing cellular iron induces a 
dystrophic/senescent phenotype.
MODEL MICROGLIA AND BRAIN AGING
Understanding senescent microglia and their role is not just relevant to 
neurodegenerative diseases. Brain aging even in non-pathological conditions is 
characterised by diminished cognitive ability that could be due to impaired synaptic 
plasticity. Maintenance of synaptic plasticity has recently been recognised as an 
important role for microglia both in development but also in the adult organism (Wu
et al. 2015). Iron-fed microglia as a model for aging microglia could be used to 
investigate the role of microglia in these processes. A well-studied form of synaptic 
plasticity is long-term potentiation. Appropriate levels of ROS have been shown to 
play an important role in long-term potentiation in the hippocampus (Serrano & Klann 
2004). Both aged and iron-fed microglia show dysregulated release of ROS which 
could affect these processes. Additionally, overproduction of IL-1β by microglia has 
also been linked to impaired long-term potentiation in the hippocampus (Patterson 
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2015). IL-1β levels are increased in iron-fed microglia providing another potential 
avenue through which brain aging could be replicated by the aged microglia model.
Genomic instability is another hallmark of aging that aged microglia could play a role 
in. It has been shown that chronic inflammation can lead to genomic instability in 
studies in the context of cancer (Lin et al. 2016, Yan et al. 2009). The fact that aged 
microglia drive increased inflammation in the aging nervous system suggests that 
they also play a role in the genomic instability seen in aging neurons (Burhans & 
Weinberger 2007). Lower levels of SIRT1 may be a key player in these events 
(Oberdoerffer et al. 2008) and conditioned medium from iron-fed microglia was 
shown to reduce SIRT1 levels in neuronal cells (unpublished data). This suggests 
that iron-fed microglia could potentially induce genomic instability in neurons thus 
expanding the role that aged microglia could play in inducing overall brain aging.
CONCLUSIONS
We began this review with the question as to whether senescent microglia could be 
the key to understanding the cause of neurodegenerative diseases. More than 25 
years of research have pointed frequently at the role of microglia in 
neurodegenerative diseases. The case for this is overwhelming. The fact that 
microglia are also known to play a supportive positive role also clearly points to there 
being a specific subset of microglia being the potential culprits. Identification, of this 
subset has not being achieved. However, as the majority of sporadic 
neurodegenerative diseases occur in patients beyond the age of 50, the probability 
that this is subset of microglia are those with a senescent/dystrophic phenotype is 
extremely high. As working with aged animals is difficult then the creation of an in 
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vitro model of aging is the best possible option to increase insight into the potential 
role of aged microglia. Creation of a model such as ours means that aged microglia 
could potentially be incorporated into both in vitro and in vivo studies of these 
neurodegenerative diseases and also aging itself. One of the biggest potential 
impacts this model could have is in pioneering reversal of the effects of aging in 
microglia. Successfully reversing the iron-overloaded phenotype could lead to not 
only greater understanding of the aging process but also in powerful brain anti-aging 
treatments that could protect older individuals from developing debilitating 
neurodegenerative diseases.
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FIGURE LEGENDS
Figure 1 Microglia in the brain. Healthy microglial cells play a myriad of supportive 
roles in the brain including sensing, intercellular communication, promotion of 
inflammation, degradation and repair. 
Figure 2 Characteristics of microglial aging. When microglia age they lose 
process ramification, develop process abnormalities and exhibit cytoplasmic 
fragmentation. They show increased iron storage and ferritin expression. Their 
increased release of neurotoxic substances and reduced ability to phagocytose 
debris and toxic protein aggregates leaves neurons vulnerable.
Figure 3 Microglial aging model induced by iron. This figure summarizes the 
effects caused by iron accumulation in aging microglia. It leads to an altered 
microglial morphology and altered intracellular processes namely increased ER 
stress leading to decreased autophagy. That leads to decreased release of IDE 
which results in decreased degradation of β-amyloid in the extracellular space. Iron 
accumulation also leads to increased secretion of inflammatory cytokines and ROS 
from which TNF-α causes increases in α-synuclein levels and toxicity in neurons 
mediated through FOXO3a.
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